Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
13.65B
Market cap13.65B
Price-Earnings ratio
-49.29
Price-Earnings ratio-49.29
Dividend yield
Dividend yield
Average volume
1.93M
Average volume1.93M
High today
$84.96
High today$84.96
Low today
$82.00
Low today$82.00
Open price
$84.21
Open price$84.21
Volume
1.02M
Volume1.02M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

With a market cap of 13.65B, Ionis Pharmaceuticals(IONS) trades at $84.35. The stock has a price-to-earnings ratio of -49.29.

On 2026-02-12, Ionis Pharmaceuticals(IONS) stock moved within a range of $82.00 to $84.96. With shares now at $84.35, the stock is trading +2.9% above its intraday low and -0.7% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 1.02M, versus its average volume of 1.93M.

The stock's 52-week range extends from a low of $23.95 to a high of $86.74.

The stock's 52-week range extends from a low of $23.95 to a high of $86.74.

IONS News

TipRanks 6d
Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $87 from $77 and keeps an Overweight rating on the shares. Following a number of...

Simply Wall St 7d
Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential

Ionis Pharmaceuticals (NasdaqGS:IONS) received European Commission approval for Dawnzera to help prevent hereditary angioedema attacks in eligible patients. Th...

Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential

Analyst ratings

71%

of 24 ratings
Buy
70.8%
Hold
29.2%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.